NanoVibronix, Inc. (NAOV)
- Previous Close
0.5620 - Open
0.6800 - Bid --
- Ask 0.7055 x 100
- Day's Range
0.5901 - 0.8099 - 52 Week Range
0.4580 - 1.5500 - Volume
4,186,549 - Avg. Volume
37,667 - Market Cap (intraday)
1.726M - Beta (5Y Monthly) 1.50
- PE Ratio (TTM)
-- - EPS (TTM)
-1.2900 - Earnings Date Nov 11, 2024 - Nov 15, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
NanoVibronix, Inc., through its subsidiary, NanoVibronix Ltd., focuses on the non-invasive biological response-activating devices that target biofilm prevention, wound healing, and pain therapy in the United States, Israel, Europe, Australia, India, and internationally. The company's product portfolio includes UroShield, an ultrasound-based product to prevent bacterial colonization and biofilm in urinary catheters, enhance antibiotic efficacy, and decrease pain and discomfort associated with urinary catheter use. It also offers PainShield, a patch-based therapeutic ultrasound technology to treat pain, muscle spasm, and joint contractures; and WoundShield, a patch-based therapeutic ultrasound device intended to facilitate tissue regeneration and wound healing by using ultrasound to increase local capillary perfusion and tissue oxygenation. It sells its products directly to patients, as well as through distributor agreements. The company was incorporated in 2003 and is headquartered in Tyler, Texas.
www.nanovibronix.comRecent News: NAOV
View MorePerformance Overview: NAOV
Trailing total returns as of 10/14/2024, which may include dividends or other distributions. Benchmark is
.YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: NAOV
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: NAOV
View MoreValuation Measures
Market Cap
1.63M
Enterprise Value
-408.15k
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.39
Price/Book (mrq)
0.57
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-83.49%
Return on Assets (ttm)
-29.57%
Return on Equity (ttm)
-140.59%
Revenue (ttm)
3.37M
Net Income Avi to Common (ttm)
-2.82M
Diluted EPS (ttm)
-1.2900
Balance Sheet and Cash Flow
Total Cash (mrq)
2.17M
Total Debt/Equity (mrq)
4.68%
Levered Free Cash Flow (ttm)
-861.75k
Research Analysis: NAOV
View MoreCompany Insights: NAOV
NAOV does not have Company Insights